Business Essential Properties outlines 2026 AFFO per share guidance growth up to 8% while capitalizing on resilient credit trends
Business Karyopharm signals $130M–$150M revenue target for 2026 with pivotal myelofibrosis data readout ahead
Business Fcpt signals continued portfolio diversification and targets increased acquisition activity in 2026
Business Darling Ingredients signals optimism for 2026 as core EBITDA guidance set at $240M–$250M for Q1